Revenue mix
Build on API supply through longer-duration CDMO customer programs and deeper development relationships.
Our transformation
Evolution.
Not a departure.
APIs remain the scientific and manufacturing foundation. Morepen is building deeper capabilities, greater scale and longer-duration customer relationships on that base.
Morepen 2.0
Four connected
transformations.
The September 2026 AGM address sets out four changes: revenue mix, EBITDA profile, scale and capability.
The business ambition is a more capable pharmaceutical manufacturing partner, supported by disciplined execution and investment.
EBITDA profile
Improve the quality of earnings through business mix, value addition and utilisation. The future trajectory remains an objective, not a guarantee.
Scale
614 KL installed capacity provides a base for the phased 800, 1000 and 1200 KL roadmap.
Capability
Strengthen complex chemistry, high-potency APIs, oncology and the selective development of new scientific platforms.
Current and future
Separate readiness
from ambition.
Current foundation: small molecules, process chemistry, APIs and commercial CDMO execution.
Capability development: high-potency and oncology facilities are described in the AGM address; project-specific suitability and containment documentation need confirmation.
Proposed or selective development: the Innovation Hub, peptides, oligonucleotides and differentiated formulation opportunities.
Explore R&D & innovationLet's build your next program.
Start a conversation about your API, development or manufacturing requirements.